MicroRNA May Help Predict Ovarian Cancer Response, University of California, San Francisco (UCSF) Study

MedPageToday -- ORLANDO -- Changes in expression of a microRNA showed potential for predicting response to the angiogenesis inhibitor bevacizumab (Avastin) in recurrent serous ovarian cancer, according to results of a small study reported here.